Proteomics Analysis of Human Amniotic Fluid *S

Amniotic fluid is a dynamic and complex mixture that reflects the physiological status of the developing fetus. In this study, the human amniotic fluid (AF) proteome of a 16–18-week normal pregnancy was profiled and analyzed to investigate the composition and functions of this fluid. Due to the complexity of AF, we utilized three different fractionation strategies to provide greater coverage. Two types of two-dimensional LC/MS/MS as well as an LC-SDS-PAGE-LC-MS/MS platform were used. A total of 16 AF samples between gestational ages of 16 and 18 weeks from women carrying chromosomally normal fetuses were analyzed by one of the three fractionation methods followed by a common reverse phase LC-MS/MS step. Mascot and The Global Proteome Machine engines were used to search the International Protein Index human database for peptide sequence identification. The list of proteins was generated by combining the results of both engines through the PeptideProphet of Scaffold software. All identified proteins were combined to generate the AF proteome comprising 1,026 unique gene matches or 842 non-redundant proteins. This list includes most of the currently used biomarkers for pregnancy-associated pathologic conditions such as preterm delivery, intra-amniotic infection, and chromosomal anomalies of the fetus. The subcellular localization, tissue expression, functions, and networks of the AF proteome were analyzed by various bioinformatic tools. These data will contribute to the better understanding of amniotic fluid function and to the discovery of novel biomarkers for prenatal diagnosis of fetal abnormalities.

[1]  Y. Takeda,et al.  The Imbalance of Plasminogen Activators and Inhibitor in Preeclampsia , 1996, The journal of obstetrics and gynaecology research.

[2]  Magnus Palmblad,et al.  Explorative study of the protein composition of amniotic fluid by liquid chromatography electrospray ionization Fourier transform ion cyclotron resonance mass spectrometry. , 2004, Journal of proteome research.

[3]  Roberto Raggiaschi,et al.  A two‐dimensional protein map of human amniotic fluid at 17 weeks' gestation , 1997, Electrophoresis.

[4]  T. Veenstra,et al.  Characterization of the Low Molecular Weight Human Serum Proteome*S , 2003, Molecular & Cellular Proteomics.

[5]  Alexey I Nesvizhskii,et al.  Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. , 2002, Analytical chemistry.

[6]  H. Augustin,et al.  Circulating endothelial cell adhesion molecules as diagnostic markers for the early identification of pregnant women at risk for development of preeclampsia. , 1997, American journal of obstetrics and gynecology.

[7]  S. Hooper,et al.  Feto-placental hypoxemia regulates the release of fetal activin A and prostaglandin E(2). , 2001, Endocrinology.

[8]  R. Iozzo,et al.  The role of proteomics in the assessment of premature rupture of fetal membranes. , 2005, Clinica chimica acta; international journal of clinical chemistry.

[9]  C. Buhimschi,et al.  Proteomic biomarker analysis of amniotic fluid for identification of intra‐amniotic inflammation , 2005, BJOG : an international journal of obstetrics and gynaecology.

[10]  Henrik Zetterberg,et al.  Proteomic analysis using protein chips to detect biomarkers in cervical and amniotic fluid in women with intra-amniotic inflammation. , 2005, Journal of proteome research.

[11]  N. Uldbjerg,et al.  Preterm delivery predicted by soluble CD163 and CRP in women with symptoms of preterm delivery , 2005, BJOG : an international journal of obstetrics and gynaecology.

[12]  J. Rossier,et al.  Proteome analysis of human plasma and amniotic fluid by Off‐Gel™ isoelectric focusing followed by nano‐LC‐MS/MS , 2006, Electrophoresis.

[13]  J. Lapidus,et al.  Diagnosis of intra-amniotic infection by proteomic profiling and identification of novel biomarkers. , 2004, JAMA.

[14]  S. Oh,et al.  Proteome analysis of human amnion and amniotic fluid by two‐dimensional electrophoresis and matrix‐assisted laser desorption/ionization time‐of‐flight mass spectrometry , 2006, Proteomics.

[15]  N. Cairns,et al.  Increased glyceraldehyde 3-phosphate dehydrogenase levels in the brain of patients with Down's syndrome , 1999, Neuroscience Letters.

[16]  G. Tsangaris,et al.  The normal human amniotic fluid supernatant proteome. , 2006, In vivo.

[17]  A. Hartikainen,et al.  Evaluation of a rapid strip test for insulin-like growth factor binding protein-1 in the diagnosis of ruptured fetal membranes. , 1996, Clinica chimica acta; international journal of clinical chemistry.

[18]  W. Gilbert,et al.  Amniotic Fluid: Not Just Fetal Urine Anymore , 2005, Journal of Perinatology.

[19]  B. Dastugue,et al.  Identification of biologic markers of the premature rupture of fetal membranes: Proteomic approach , 2003, Proteomics.

[20]  S. Hooper,et al.  Feto-Placental Hypoxemia Regulates the Release of Fetal Activin A and Prostaglandin E2. , 2001, Endocrinology.

[21]  G. Tsangaris,et al.  Proteomic analysis of amniotic fluid in pregnancies with Down syndrome , 2006, Proteomics.

[22]  M. Mazor,et al.  Amniotic fluid intercellular adhesion molecule-1 is a marker for Ureaplasma infection in women with preterm labor. , 2006, American journal of obstetrics and gynecology.

[23]  E. Wallace,et al.  Amniotic fluid levels of dimeric inhibins, pro‐αC inhibin, activin A and follistatin in Down's syndrome , 1999, Clinical endocrinology.

[24]  T. Stubbs,et al.  Plasma fibronectin levels in preeclampsia: a possible biochemical marker for vascular endothelial damage. , 1984, American journal of obstetrics and gynecology.

[25]  W. Barrett,et al.  Differences among techniques for high‐abundant protein depletion , 2005, Proteomics.

[26]  David C Muddiman,et al.  Evaluation of protein depletion methods for the analysis of total-, phospho- and glycoproteins in lumbar cerebrospinal fluid. , 2005, Journal of proteome research.